{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:04:06Z","timestamp":1789722246498,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00894-026-06894-2","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:11:50Z","timestamp":1786518710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational techniques to study breast cancer scaffolds for antiangiogenesis: a review"],"prefix":"10.1007","volume":"32","author":[{"given":"Robin","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Luxmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"6894_CR1","doi-asserted-by":"crossref","unstructured":"Chandraprasad MS, Dey A, Swamy MK (2022) Introduction to cancer and treatment approaches. In: Paclitaxel.\u00a0Academic Press, pp 1\u201327","DOI":"10.1016\/B978-0-323-90951-8.00010-2"},{"key":"6894_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"key":"6894_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","author":"RL Siegel","year":"2022","unstructured":"Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6894_CR4","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"6894_CR5","doi-asserted-by":"crossref","unstructured":"Correia AS, G\u00e4rtner F, Vale N (2021) Drug combination and repurposing for cancer therapy: the example of breast cancer. Heliyon 7(1)","DOI":"10.1016\/j.heliyon.2021.e05948"},{"key":"6894_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-015-0049-8","volume":"9","author":"Q Song","year":"2015","unstructured":"Song Q, Merajver SD, Li JZ (2015) Cancer classification in the genomic era: five contemporary problems. Hum Genomics 9:1\u20138","journal-title":"Hum Genomics"},{"key":"6894_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02804-0","volume":"37","author":"A de Cristo Soares Alves","year":"2020","unstructured":"de Cristo Soares Alves A et al (2020) Chitosan-coated lipid-core nanocapsules functionalized with gold-III and bevacizumab induced in vitro cytotoxicity against C6 cell line and in vivo potent antiangiogenic activity. Pharm Res 37:1\u201317","journal-title":"Pharm Res"},{"key":"6894_CR8","doi-asserted-by":"publisher","DOI":"10.1039\/d5md00849b","author":"PA Yakkala","year":"2025","unstructured":"Yakkala PA et al (2025) Recent developments in the discovery of indole-based scaffolds as promising targeted cancer therapeutics. RSC Med Chem. https:\/\/doi.org\/10.1039\/d5md00849b","journal-title":"RSC Med Chem"},{"issue":"1","key":"6894_CR9","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1038\/s41598-020-65584-y","volume":"10","author":"A L\u00f3pez-Cort\u00e9s","year":"2020","unstructured":"L\u00f3pez-Cort\u00e9s A et al (2020) Prediction of breast cancer proteins involved in immunotherapy, metastasis, and RNA-binding using molecular descriptors and artificial neural networks. Sci Rep 10(1):8515","journal-title":"Sci Rep"},{"issue":"4","key":"6894_CR10","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ac6922","volume":"17","author":"S Singh","year":"2022","unstructured":"Singh S et al (2022) Cellular studies and sustained drug delivery via nanostructures fabricated on 3D printed porous Neovius lattices of Ti6Al4V ELI. Biomed Mater 17(4):045004","journal-title":"Biomed Mater"},{"issue":"2","key":"6894_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/cbt.11.2.13959","volume":"11","author":"SM Raja","year":"2011","unstructured":"Raja SM et al (2011) Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 11(2):263\u2013276","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"6894_CR12","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1080\/07391102.2023.2226744","volume":"42","author":"SK Patnaik","year":"2024","unstructured":"Patnaik SK et al (2024) Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy. J Biomol Struct Dyn 42(11):5551\u20135574","journal-title":"J Biomol Struct Dyn"},{"key":"6894_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2025.102507","author":"U Yousuf","year":"2025","unstructured":"Yousuf U et al (2025) Bioinformatics and computational studies of marine natural products in identifying novel VEGFR-2 inhibitors for breast cancer treatment. Results Chem. https:\/\/doi.org\/10.1016\/j.rechem.2025.102507","journal-title":"Results Chem"},{"issue":"8","key":"6894_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/bioengineering9080335","volume":"9","author":"MM Rahman","year":"2022","unstructured":"Rahman MM et al (2022) Emerging promise of computational techniques in anti-cancer research: at a glance. Bioengineering (Basel) 9(8):335","journal-title":"Bioengineering (Basel)"},{"key":"6894_CR15","doi-asserted-by":"crossref","unstructured":"Gupta A, Kumar S, Maurya VK, Puri B, Saxena SK\u00a0(2022) High-throughput screening for drug discovery toward infectious diseases:\u00a0options and challenges. In High-Throughput Screening for Drug Discovery. IntechOpen","DOI":"10.5772\/intechopen.102936"},{"key":"6894_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40484-019-0172-y","volume":"7","author":"J Fan","year":"2019","unstructured":"Fan J, Fu A, Zhang L (2019) Progress in molecular docking. Quant Biol 7:83\u201389","journal-title":"Quant Biol"},{"issue":"5","key":"6894_CR17","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1021\/acs.jmedchem.0c02227","volume":"64","author":"A Fischer","year":"2021","unstructured":"Fischer A et al (2021) Decision making in structure-based drug discovery: visual inspection of docking results. J Med Chem 64(5):2489\u20132500","journal-title":"J Med Chem"},{"issue":"4","key":"6894_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1550","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) Systems biology of angiogenesis signaling: computational models and omics. WIREs Mech Dis 14(4):e1550","journal-title":"WIREs Mech Dis"},{"issue":"6","key":"6894_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4103\/ijdr.IJDR_534_16","volume":"28","author":"P Rajaram","year":"2017","unstructured":"Rajaram P et al (2017) Epidermal growth factor receptor: role in human cancer. Indian J Dent Res 28(6):687\u2013694","journal-title":"Indian J Dent Res"},{"issue":"1","key":"6894_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11302-025-10119-1","volume":"22","author":"FC da Silva","year":"2026","unstructured":"da Silva FC et al (2026) The purinergic signaling interfaces in breast cancer angiogenesis. Purinergic Signal 22(1):13","journal-title":"Purinergic Signal"},{"key":"6894_CR21","doi-asserted-by":"publisher","first-page":"1288652","DOI":"10.3389\/fmolb.2023.1288652","volume":"10","author":"S Baammi","year":"2023","unstructured":"Baammi S, El Allali A, Daoud R (2023) Potent VEGFR-2 inhibitors for resistant breast cancer: a comprehensive 3D-QSAR, ADMET, molecular docking and MMPBSA calculation on triazolopyrazine derivatives. Front Mol Biosci 10:1288652","journal-title":"Front Mol Biosci"},{"issue":"24","key":"6894_CR22","doi-asserted-by":"publisher","first-page":"14720","DOI":"10.1021\/acsomega.0c01511","volume":"5","author":"DS Jairajpuri","year":"2020","unstructured":"Jairajpuri DS et al (2020) Identification of sphingosine kinase-1 inhibitors from bioactive natural products targeting cancer therapy. ACS Omega 5(24):14720\u201314729","journal-title":"ACS Omega"},{"issue":"4","key":"6894_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/jpm10040200","volume":"10","author":"M \u00c1valos-Moreno","year":"2020","unstructured":"\u00c1valos-Moreno M et al (2020) Drug repurposing for triple-negative breast cancer. J Pers Med 10(4):200","journal-title":"J Pers Med"},{"issue":"11","key":"6894_CR24","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.21037\/tcr-20-1992","volume":"9","author":"J Chen","year":"2020","unstructured":"Chen J et al (2020) Limonin inhibits angiogenesis and metastasis of human breast cancer cells by suppressing the VEGFR2\/IGFR1-mediated STAT3 signaling pathway. Transl Cancer Res 9(11):6820","journal-title":"Transl Cancer Res"},{"issue":"10","key":"6894_CR25","doi-asserted-by":"publisher","first-page":"16643","DOI":"10.1002\/jcb.28923","volume":"120","author":"NA Amrutha","year":"2019","unstructured":"Amrutha NA et al (2019) Pyridine derivatives as anticancer lead compounds with fatty acid synthase as the target: an in silico-guided in vitro study. J Cell Biochem 120(10):16643\u201316657","journal-title":"J Cell Biochem"},{"key":"6894_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101467","volume":"7","author":"S-f Yan","year":"2024","unstructured":"Yan S-f et al (2024) Advances in endothelial cell lipid metabolism and tumor angiogenesis. Results Chem 7:101467","journal-title":"Results Chem"},{"issue":"2","key":"6894_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bmcl.2016.11.059","volume":"27","author":"R Huang","year":"2017","unstructured":"Huang R et al (2017) Virtual screening and biophysical studies lead to HSP90 inhibitors. Bioorg Med Chem Lett 27(2):277\u2013281","journal-title":"Bioorg Med Chem Lett"},{"key":"6894_CR28","doi-asserted-by":"crossref","unstructured":"Wang X et al (2026) Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications. Mol Cancer 25(1):102","DOI":"10.1186\/s12943-025-02559-5"},{"key":"6894_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112162","volume":"191","author":"LI Pilkington","year":"2020","unstructured":"Pilkington LI et al (2020) Development, synthesis and biological investigation of a novel class of potent PC-PLC inhibitors. Eur J Med Chem 191:112162","journal-title":"Eur J Med Chem"},{"issue":"3","key":"6894_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/cbdd.13606","volume":"95","author":"Y Zhao","year":"2020","unstructured":"Zhao Y et al (2020) Discovery of novel PC-PLC activity inhibitors. Chem Biol Drug Des 95(3):380\u2013387","journal-title":"Chem Biol Drug Des"},{"key":"6894_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1231875","volume":"13","author":"Y-N Wu","year":"2023","unstructured":"Wu Y-N et al (2023) The roles of phospholipase C-\u03b2 related signals in the proliferation, metastasis and angiogenesis of malignant tumors, and the corresponding protective measures. Front Oncol 13:1231875","journal-title":"Front Oncol"},{"issue":"2","key":"6894_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.47262\/SL\/9.2.132021007","volume":"9","author":"DS Metibemu","year":"2021","unstructured":"Metibemu DS (2021) 3D-QSAR and molecular docking approaches for the identification of novel phyto-inhibitors of the cyclin-dependent kinase 4. Sci Lett 9(2):42\u201348","journal-title":"Sci Lett"},{"key":"6894_CR33","unstructured":"Tang R (2018) PTPN2 inhibitors sensitize melanoma tumor cells to immunotherapy.\u00a0Doctoral dissertation, UC San Diego"},{"issue":"1","key":"6894_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06131-0","volume":"7","author":"S Alam","year":"2017","unstructured":"Alam S, Khan F (2017) 3D-QSAR studies on Maslinic acid analogs for anticancer activity against breast cancer cell line MCF-7. Sci Rep 7(1):6019","journal-title":"Sci Rep"},{"key":"6894_CR35","doi-asserted-by":"crossref","unstructured":"Dhasmana A et al (2019) High-throughput virtual screening (HTVS) of natural compounds and exploration of their biomolecular mechanisms: an in silico approach. In: New look to phytomedicine. Elsevier, pp 523\u2013548","DOI":"10.1016\/B978-0-12-814619-4.00020-3"},{"issue":"2","key":"6894_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.51511\/pr.82","volume":"4","author":"V Aprilia","year":"2024","unstructured":"Aprilia V et al (2024) Evaluation of natural compounds as VEGFR-2 inhibitors for breast cancer therapy: insights from molecular docking and drug-likeness analysis. Pharm Rep 4(2):82\u201382","journal-title":"Pharm Rep"},{"issue":"40","key":"6894_CR37","doi-asserted-by":"publisher","first-page":"67457","DOI":"10.18632\/oncotarget.19084","volume":"8","author":"B Ozsvari","year":"2017","unstructured":"Ozsvari B et al (2017) Mitoriboscins: mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget 8(40):67457","journal-title":"Oncotarget"},{"issue":"1","key":"6894_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H et al (2025) Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther 10(1):245","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"6894_CR39","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1021\/acs.jcim.9b01101","volume":"60","author":"D Stumpfe","year":"2020","unstructured":"Stumpfe D, Bajorath J (2020) Current trends, overlooked issues, and unmet challenges in virtual screening. J Chem Inf Model 60(9):4112\u20134115","journal-title":"J Chem Inf Model"},{"issue":"7","key":"6894_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17460441.2019.1604677","volume":"14","author":"O Slater","year":"2019","unstructured":"Slater O, Kontoyianni M (2019) The compromise of virtual screening and its impact on drug discovery. Expert Opin Drug Discov 14(7):619\u2013637","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"6894_CR41","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1039\/D5MD00053J","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J et al (2025) Discovery of novel STAT3 inhibitors with anti-breast cancer activity: structure-based virtual screening, molecular dynamics and biological evaluation. RSC Med Chem 16(6):2848\u20132865","journal-title":"RSC Med Chem"},{"key":"6894_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.steroids.2018.03.010","volume":"134","author":"D Montes-Grajales","year":"2018","unstructured":"Montes-Grajales D, Mart\u00ednez-Romero E, Olivero-Verbel J (2018) Phytoestrogens and mycoestrogens interacting with breast cancer proteins. Steroids 134:9\u201315","journal-title":"Steroids"},{"key":"6894_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.abb.2019.07.002","volume":"671","author":"O Mucha","year":"2019","unstructured":"Mucha O et al (2019) Development and characterization of a new inhibitor of heme oxygenase activity for cancer treatment. Arch Biochem Biophys 671:130\u2013142","journal-title":"Arch Biochem Biophys"},{"key":"6894_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-021-03411-1","volume":"21","author":"MH Mahnashi","year":"2021","unstructured":"Mahnashi MH, Alqahtani YS, Alyami BA, Alqarni AO, Ullah F, Wadood A, Sadiq A, Shareef A, Ayaz M (2021) Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L. BMC Complement Med Ther 21:1\u2013239","journal-title":"BMC Complement Med Ther"},{"key":"6894_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1135898","volume":"14","author":"WR Mir","year":"2023","unstructured":"Mir WR et al (2023) Network pharmacology combined with molecular docking and in vitro verification reveals the therapeutic potential of Delphinium roylei munz constituents on breast carcinoma. Front Pharmacol 14:1135898","journal-title":"Front Pharmacol"},{"issue":"15","key":"6894_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512479","volume":"24","author":"R Wang","year":"2023","unstructured":"Wang R et al (2023) Integrated transcriptome and molecular docking to identify the hub superimposed attenuation targets of curcumin in breast cancer cells. Int J Mol Sci 24(15):12479","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6894_CR47","first-page":"356","volume":"9","author":"E Alves","year":"2024","unstructured":"Alves E et al (2024) Targeting breast cancer: unveiling FN3K enzyme inhibitors via structure-based virtual screening and molecular dynamic simulation. Int J Novel Res Dev 9(6):356\u2013384","journal-title":"Int J Novel Res Dev"},{"issue":"3","key":"6894_CR48","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1080\/10406638.2023.2201457","volume":"44","author":"A Zochedh","year":"2024","unstructured":"Zochedh A et al (2024) DFT simulation of berberine chloride with spectroscopic characterization-biological activity and molecular docking against breast cancer. Polycycl Aromat Compd 44(3):1556\u20131580","journal-title":"Polycycl Aromat Compd"},{"issue":"1","key":"6894_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/qua.27299","volume":"124","author":"K Chandran","year":"2024","unstructured":"Chandran K et al (2024) Quantum chemical calculation, topological analysis, biological evaluation and molecular docking of allo-ocimenol against breast cancer. Int J Quantum Chem 124(1):e27299","journal-title":"Int J Quantum Chem"},{"key":"6894_CR50","unstructured":"Nadar S, Borkar MR, Khan T (2024) Identification of potential focal adhesion kinase (FAK) inhibitors: a molecular modeling approach. J Biomol Struct Dyn 1\u201311"},{"issue":"1","key":"6894_CR51","doi-asserted-by":"publisher","first-page":"25883","DOI":"10.1038\/s41598-025-11177-6","volume":"15","author":"A Hossam","year":"2025","unstructured":"Hossam A et al (2025) Discovery of natural scaffolds as HER2 inhibitors for breast cancer: virtual screening, molecular dynamics, and biological characterization with selectivity profiling. Sci Rep 15(1):25883","journal-title":"Sci Rep"},{"issue":"1","key":"6894_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12906-024-04415-3","volume":"24","author":"L Ralte","year":"2024","unstructured":"Ralte L et al (2024) Identification of novel AKT1 inhibitors from Sapria himalayana bioactive compounds using structure-based virtual screening and molecular dynamics simulations. BMC Complement Med Ther 24(1):116","journal-title":"BMC Complement Med Ther"},{"issue":"3","key":"6894_CR53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","volume":"10","author":"H Chen","year":"2024","unstructured":"Chen H et al (2024) Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment. ACS Cent Sci 10(3):579\u2013594","journal-title":"ACS Cent Sci"},{"issue":"6","key":"6894_CR54","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1007\/s11030-024-11075-5","volume":"29","author":"S Kumar","year":"2025","unstructured":"Kumar S et al (2025) Computational screening and molecular dynamics of natural compounds targeting the SH2 domain of STAT3: a multitarget approach using network pharmacology. Mol Divers 29(6):5607\u20135633","journal-title":"Mol Divers"},{"key":"6894_CR55","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S581878","author":"NJ Iravani","year":"2026","unstructured":"Iravani NJ et al (2026) Synergistic inhibition of angiogenesis and tumor progression by CD73 inhibitor and menstrual blood stem cell-derived exosomes via miR-422a upregulation in HER2-positive breast cancer. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S581878","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-026-06894-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:51:02Z","timestamp":1789721462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-026-06894-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6894"],"URL":"https:\/\/doi.org\/10.1007\/s00894-026-06894-2","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"305"}}